For the Inventor, By the Inventor

Enter assignee name

Medshine Discovery Inc.

USPTO Granted Patents = 72

% Expired Patents = 5.6

CIPO Patents = 17

EPO Patents = 39

Forward Citations = 58

Loading Chart...

Loading Chart...

179 inventors (with patents filed for the assignee):

Shuhui Chen (59 out of 234 patents)

Jian Li (33 out of 234 patents)

Charles Z Ding (15 out of 56 patents)

4. Guoping Hu (12 out of 37 patents)

5. Lingyun Wu (10 out of 27 patents)

6. Yunfu Luo (10 out of 40 patents)

7. Haiying He (8 out of 60 patents)

8. Wenyuan Qian (8 out of 23 patents)

9. Lihong Hu (7 out of 32 patents)

10. Kevin X Chen (7 out of 32 patents)

11. Maoyi Lei (7 out of 11 patents)

12. Shuhui Chen (7 out of 130 patents)

13. Zhigan Jiang (6 out of 22 patents)

14. Zhaoguo Chen (6 out of 10 patents)

15. Yanxin Yu (5 out of 6 patents)

Core Competencies:

Heterocyclic Compounds

KRAS Inhibitors

LSD1 Inhibitors

SGLT1 Inhibitors

RHO Kinase Inhibitors

EGFR Inhibitors

mTORC Inhibitors

ACC Inhibitors

Caspase Inhibitors

PDE4 Inhibitors

CDK4/6 Inhibitors

Immunomodulators

72 patents: Sort by Forward Citations

1. 12741031 - Glutarimide compound and use thereof (2026-09-22),

2. 12655135 - Benzo seven-membered ring bifunctional compound and application thereof (2026-06-16),

3. 12606540 - Triazolone compound (2026-04-21),

4. 12552813 - Heterocyclic substituted pyrimidopyran compound and use thereof (2026-02-17),

5. 12552787 - Quinazoline compound (2026-02-17),

6. 12545648 - Benzopyrazole compound (2026-02-10),

7. 12479800 - Phenylpropionamide compound and use thereof (2025-11-25),

8. 12479794 - Acetophenone oxime compound and application thereof (2025-11-25),

9. 12466816 - FUSED CYCLIC COMPOUND CAPABLE OF DEGRADING PROTEIN AND USE THEREOF (2025-11-11),

10. 12421236 - Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor (2025-09-23),

11. 12351590 - Pyrrolopyrimidine compound and use thereof (2025-07-08),

12. 12351587 - Bicyclic compound as RIP-1 kinase inhibitor and application thereof (2025-07-08),

13. 12338218 - Crystal form of benzimidazole-2-one compound, solvate thereof, crystal form of solvate thereof, and preparation method thereof (2025-06-24),

14. 12258367 - Glucoside derivative that acts as SGLT1 inhibitor and application thereof (2025-03-25),

15. 12030897 - Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof (2024-07-09),

MEDSHINE DISCOVERY INC. is a biotechnology company focused on the discovery and development of innovative therapeutic solutions. With a team of experienced scientists, we aim to address unmet medical needs and improve patient outcomes. Our research and development efforts are centered around identifying novel drug targets, conducting preclinical testing, and advancing promising drug candidates into clinical trials. Through our dedication to scientific excellence, we strive to bring transformative medicines to market and make a positive impact on global healthcare.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

72 Patents

#9 in Jiangsu

#454 in China

#10,370 in the World

Medshine Discovery Inc.

Forward Citations = 58

179 inventors:

Shuhui Chen (59 out of 234 patents)

Jian Li (33 out of 234 patents)

Charles Z Ding (15 out of 56 patents)

4. Guoping Hu (12 out of 37 patents)

5. Lingyun Wu (10 out of 27 patents)

Please report any incorrect information to [email protected]

Loading…